The translational research of Lydia Meder and her team focuses on deciphering molecular signaling pathways in metastasis, particularly in lung cancer. The intercellular communication of tumor cells with immune cells and endothelial cells in the primary lesion, in the bloodstream and in the metastatic microenvironment is the central aspect of their research. They apply preclinical targeted treatment approaches in combination with immunotherapy and chemotherapy in several in vivo models. In this context, they unravel resistance mechanisms and identify biomarkers for therapy stratification.

Meder L, Orschel CI, Otto CJ, Koker M, Brägelmann J, Ercanoglu MS, Dähling S, Compes A, Selenz C, Nill M, Dietlein F, Florin A, Eich ML, Borchmann S, Odenthal M, Blazquez R, Hilberg F, Klein F, Hallek M, Büttner R, Reinhardt HC, Ullrich RT. Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis. JCI Insight. 2024 May 22;9(10):e166402. doi: 10.1172/jci.insight.166402. PMID: 38775153; PMCID: PMC11141935.

Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, Borchmann S, Wennhold K, Vlasic I, Oberbeck S, Riedel R, Florin A, Golfmann K, Schlößer HA, Odenthal M, Buettner R, Wolf J, Hallek M, Herling M, von Bergwelt-Baildon M, Reinhardt HC, Ullrich RT. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Res. 2018 Aug 1;78(15):4270-4281. doi: 10.1158/0008-5472.CAN-17-2176. Epub 2018 May 18. PMID: 29776963.

Zoom-Meeting-Link:
https://fau.zoom-x.de/j/66436559733?pwd=Wv09XOMJYYtsaahiCdGQOBurRadONj.1 

Meeting-ID: 664 3655 9733
Kenncode: 982649